Wayne Winegarden
Blog
To See the Fallacy of H.R. 3 (Lower Drug Costs Now Act) Just Look at the Inflation Data
Railing about sky high drug prices makes good political theater and helps drum up support for the latest attempt to impose drug price controls (H.R. 3 or the Lower Drug Costs Now Act). This accusation also perpetuates misinformation. If implemented, H.R. 3 would endanger patient access to current efficacious medicines ...
Blackouts
Competitive Energy Markets, Not Monopoly, Delivers Affordable, Reliable, And Low-Emission Energy
Texas’ energy debacle during this past winter has led to a great deal of introspection regarding which energy market structure is the most appropriate. Most analysts would agree that energy market regulations should facilitate access to affordable and reliable electricity, while generating the lowest feasible emissions. The controversy arises with ...
Business & Economics
Wayne Winegarden Quoted in Business Insider on American Inflation Woes
Inflation is seen as the stock market’s boogeyman as the economy recovers. We asked 3 experts if the fears are warranted – or if concerns are overblown. By Will Daniel On April 29, new data showed that a key measure of inflation monitored by the Fed – core PCE (personal ...
Business & Economics
It’s Time For A Supply-Side Resurgence
The Biden administration’s multi-trillion-dollar stimulus and spending policies are exclusively demand-side measures aimed at supporting the consumer. But this focus is blinding the Biden team from mounting economic crises that are resulting from this anti-growth agenda. Instead, the federal government desperately needs to implement a comprehensive supply-side agenda – low-taxes, ...
Blog
Biden’s Destructive Corporate Income Tax Hike
The New York Times has a summary of the Biden Tax Plan claiming to explain “some of the main provisions included in the plan and how they’re intended to work.” While the Times may have accurately explained how the Administration “intends” for the tax hike to work, these intentions are ...
Blog
Here They Go Again: The Democratic Obsession with Drug Price Controls Will Harm Patients and Diminish Innovation
The U.S. House of Representatives is once again considering “The Lower Drug Costs Now Act”. It was a bad idea in the last Congress, and it is still bad policy today. If it becomes law, this Act (H.R. 3) empowers the federal government to negotiate prices on select drugs for ...
Climate Change
President Biden’s 50% Emissions Reduction Target Is Political Theater, Not Serious Policy
At the 2021 global climate summit, President Biden committed the U.S. to cut its greenhouse gas emissions in half by 2030. Cutting emissions in half is a great talking point and a satisfying sounding goal. Unfortunately, the 50% – 52% reduction goal is more of a political statement than an achievable policy. ...
Blog
Corrupting Infrastructure in Order to Expand the Federal Government’s Size and Scope
Allusions to George Orwell’s 1984 are often overdone, but the applicability is simply too great to ignore. After all, how else do you refer to a proposed $2.7 trillion infrastructure package that spends only 16-cents on the dollar for infrastructure? Having reviewed the President’s proposed package based on the White ...
Commentary
Violating intellectual property rights jeopardizes quality health care
Policymakers across the globe are attempting to vilify the same private companies that have been invaluable partners in the fight against the COVID-19 pandemic. If these efforts are successful, it will be patients who are harmed the most. Globally, the World Trade Organization (WTO) wants to waive the patent rights for the ...
California
Green Jobs Demonstrate The Perils Of Government-Directed Economic Growth
Part of President Biden’s Build Back Better initiative promises to “create good-paying union jobs and train Americans for jobs of the future.” The unspoken theory behind this initiative is that green jobs will offer a pay premium to workers compared to jobs in the fossil fuel industry. It also reflects the Administration’s ...
To See the Fallacy of H.R. 3 (Lower Drug Costs Now Act) Just Look at the Inflation Data
Railing about sky high drug prices makes good political theater and helps drum up support for the latest attempt to impose drug price controls (H.R. 3 or the Lower Drug Costs Now Act). This accusation also perpetuates misinformation. If implemented, H.R. 3 would endanger patient access to current efficacious medicines ...
Competitive Energy Markets, Not Monopoly, Delivers Affordable, Reliable, And Low-Emission Energy
Texas’ energy debacle during this past winter has led to a great deal of introspection regarding which energy market structure is the most appropriate. Most analysts would agree that energy market regulations should facilitate access to affordable and reliable electricity, while generating the lowest feasible emissions. The controversy arises with ...
Wayne Winegarden Quoted in Business Insider on American Inflation Woes
Inflation is seen as the stock market’s boogeyman as the economy recovers. We asked 3 experts if the fears are warranted – or if concerns are overblown. By Will Daniel On April 29, new data showed that a key measure of inflation monitored by the Fed – core PCE (personal ...
It’s Time For A Supply-Side Resurgence
The Biden administration’s multi-trillion-dollar stimulus and spending policies are exclusively demand-side measures aimed at supporting the consumer. But this focus is blinding the Biden team from mounting economic crises that are resulting from this anti-growth agenda. Instead, the federal government desperately needs to implement a comprehensive supply-side agenda – low-taxes, ...
Biden’s Destructive Corporate Income Tax Hike
The New York Times has a summary of the Biden Tax Plan claiming to explain “some of the main provisions included in the plan and how they’re intended to work.” While the Times may have accurately explained how the Administration “intends” for the tax hike to work, these intentions are ...
Here They Go Again: The Democratic Obsession with Drug Price Controls Will Harm Patients and Diminish Innovation
The U.S. House of Representatives is once again considering “The Lower Drug Costs Now Act”. It was a bad idea in the last Congress, and it is still bad policy today. If it becomes law, this Act (H.R. 3) empowers the federal government to negotiate prices on select drugs for ...
President Biden’s 50% Emissions Reduction Target Is Political Theater, Not Serious Policy
At the 2021 global climate summit, President Biden committed the U.S. to cut its greenhouse gas emissions in half by 2030. Cutting emissions in half is a great talking point and a satisfying sounding goal. Unfortunately, the 50% – 52% reduction goal is more of a political statement than an achievable policy. ...
Corrupting Infrastructure in Order to Expand the Federal Government’s Size and Scope
Allusions to George Orwell’s 1984 are often overdone, but the applicability is simply too great to ignore. After all, how else do you refer to a proposed $2.7 trillion infrastructure package that spends only 16-cents on the dollar for infrastructure? Having reviewed the President’s proposed package based on the White ...
Violating intellectual property rights jeopardizes quality health care
Policymakers across the globe are attempting to vilify the same private companies that have been invaluable partners in the fight against the COVID-19 pandemic. If these efforts are successful, it will be patients who are harmed the most. Globally, the World Trade Organization (WTO) wants to waive the patent rights for the ...
Green Jobs Demonstrate The Perils Of Government-Directed Economic Growth
Part of President Biden’s Build Back Better initiative promises to “create good-paying union jobs and train Americans for jobs of the future.” The unspoken theory behind this initiative is that green jobs will offer a pay premium to workers compared to jobs in the fossil fuel industry. It also reflects the Administration’s ...
